Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 8/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | COMT | P21964 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2171789 | 0.83 | GRM5 (0.43) | PTGS2NOTUMTGFBR1GPR52 | |
| SCHEMBL1277760 | 0.80 | NPC1 (0.38) | PTGS2NOTUMTGFBR1P2RX7MAPT | |
| SCHEMBL13944103 | 0.76 | KDM4E (0.41) | GPR52KDM4EALDH1A1 | |
| SCHEMBL1708964 | 0.71 | HPGD (0.48) | KDM4E | |
| SCHEMBL4972851 | 0.70 | GPR52 (0.36) | PTGS2TGFBR1GPR52 | |
| SCHEMBL23212166 | 0.70 | NOTUM (0.49) | PTGS2NOTUMTGFBR1P2RX7COMT | |
| SCHEMBL3095507 | 0.70 | PTGS2 (0.39) | PTGS2NOTUMKDM4EALDH1A1 | |
| SCHEMBL1699007 | 0.70 | PTGS2 (0.43) | PTGS2P2RX7ALDH1A1 | |
| SCHEMBL859562 | 0.66 | — | — | |
| SCHEMBL14445097 | 0.66 | PTGS2 (0.44) | PTGS2KDM4EPOLBL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349873-B2 | Factor XA inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349873-B2 | Factor XA inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120088795-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-20120088795-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-8063077-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063077-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20110118244-A2 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110118244-A2 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20100249117-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100249117-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2010-09-30 | — | — | US | disclosed |
| US-7767697-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-7767697-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-7763608-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763608-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20090030045-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090030045-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-01-29 | — | — | US | disclosed |
| WO-2007131179-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259924-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259924-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030045-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | PTGS2 769/4885NOTUM 272/4885TGFBR1 1440/4885 |
| US-20110118244-A2 | FACTOR XA INHIBITORS | TFPI, F12, F11 | PTGS2 769/4885NOTUM 272/4885TGFBR1 1440/4885 |
| US-20100249117-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | PTGS2 769/4885NOTUM 272/4885TGFBR1 1440/4885 |
| US-20070259924-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | PTGS2 769/4885NOTUM 272/4885TGFBR1 1440/4885 |
| US-20120088795-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | PTGS2 769/4885NOTUM 272/4885TGFBR1 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.